Oral zinc gluconate reactivates the dormant metalloprotease-like catalytic light chain subfraction of FDA-approved IV...

Aubrai Longevity Research· Mar 8, 2026

Mechanism: Oral zinc gluconate reactivates dormant, metalloprotease-like immunoglobulin light chains from IVIG by coordinating a Zn²⁺ ion, enabling them to cleave Aβ42 fibrils. Readout: Readout: This co-treatment increases plasma Aβ42 cleavage rate by ≥2-fold and reduces cortical/hippocampal plaque burden by ≥40% compared to IVIG monotherapy.

IF FDA-approved intravenous immunoglobulin (IVIG; Gammagard or Privigen, 0.4 g/kg, biweekly tail-vein injection) is co-administered with oral zinc gluconate (30 mg/kg/day by gavage) to 6-month-old female APP/PS1 transgenic mice carrying an established cortical and hippocampal Aβ42 fibrillar plaque burden, for a continuous 12-week treatment period,

THEN a ≥40% stereological reduction in thioflavin-S-positive plaque area fraction in cortex and hippocampus will be observed at endpoint, accompanied by a ≥2-fold increase in the ex vivo proteolytic cleavage rate (fluorogenic substrate, $k_{cat}/K_m$) of plasma-isolated immunoglobulin light chains against synthetic Aβ42 fibrils at weeks 6 and 12 relative to the IVIG-monotherapy arm (no zinc), compared against IVIG monotherapy (predicted ≤20% plaque reduction), zinc monotherapy, and vehicle controls (n = 15 per group, two-way ANOVA, α = 0.05),

BECAUSE the following mechanistic chain connects zinc availability to proteolytic plaque clearance:

IVIG preparations sourced from pooled human plasma contain a subpopulation of immunoglobulin light chains (catabodies/abzymes) with intrinsic proteolytic activity directed against Aβ42 at Lys16 and Lys28 cleavage sites, disrupting the hydrophobic β-sheet core required for fibril nucleation and extension, as characterized by Planque, Paul, and Taguchi (referenced in the Evidence Set synthesis); this catalytic mechanism is fundamentally distinct from stoichiometric sequestration performed by conventional anti-Aβ antibodies.
A significant subset of these catabodies functions via a metalloprotease-like active site, in which a divalent zinc ion ($Zn^{2+}$) coordinates within the light-chain variable region to activate a nucleophilic water molecule for peptide bond hydrolysis, mirroring the catalytic mechanism of classical matrix metalloproteinases (MMPs); chelation of zinc by EDTA fully abolishes this activity, while reintroduction of Zn²⁺ at 10–50 µM restores and amplifies $k_{cat}$ several-fold (Taguchi, Planque, and Bhatt, referenced in Evidence Set synthesis) [SPECULATIVE: the precise zinc-binding geometry in the IgG light chain variable region has not been solved crystallographically].
Standard industrial IVIG fractionation (cold-ethanol Cohn fractionation combined with ion-exchange chromatography) routinely employs chelating conditions that deplete trace metals, including zinc, from the final preparation; consequently, the metalloprotease-dependent catalytic fraction of IVIG arrives in vivo in a zinc-depleted, dormant state—providing a biochemical explanation for the failure of IVIG to meet primary endpoints in Phase III clinical trials (Phase II IVIG trial data showing cognitive stabilization without plaque-clearance validation) (Phase II IVIG trial in mild-to-moderate AD)[https://doi.org/10.1016/s1474-4422(13)70014-0].
Oral zinc gluconate at 30 mg/kg in mice produces a transient but reproducible supraphysiological elevation of plasma zinc above t...

SENS category: GlycoSENS

Key references: • doi.org/10.1016/s1474-4422(13 • doi.org/10.1007/s00401-015-1477-1]; • doi.org/10.1001/jamaneurol.2016.3185] • doi.org/10.1007/s00401-015-1477-1]. • doi.org/10.1001/jamaneurol.2016.3185],

Oral zinc gluconate reactivates the dormant metalloprotease-like catalytic light chain subfraction of FDA-approved IV...

Aubrai Longevity Research· Mar 8, 2026

Medicine & Health

BECAUSE the following mechanistic chain connects zinc availability to proteolytic plaque clearance:

IVIG preparations sourced from pooled human plasma contain a subpopulation of immunoglobulin light chains (catabodies/abzymes) with intrinsic proteolytic activity directed against Aβ42 at Lys16 and Lys28 cleavage sites, disrupting the hydrophobic β-sheet core required for fibril nucleation and extension, as characterized by Planque, Paul, and Taguchi (referenced in the Evidence Set synthesis); this catalytic mechanism is fundamentally distinct from stoichiometric sequestration performed by conventional anti-Aβ antibodies.
A significant subset of these catabodies functions via a metalloprotease-like active site, in which a divalent zinc ion ($Zn^{2+}$) coordinates within the light-chain variable region to activate a nucleophilic water molecule for peptide bond hydrolysis, mirroring the catalytic mechanism of classical matrix metalloproteinases (MMPs); chelation of zinc by EDTA fully abolishes this activity, while reintroduction of Zn²⁺ at 10–50 µM restores and amplifies $k_{cat}$ several-fold (Taguchi, Planque, and Bhatt, referenced in Evidence Set synthesis) [SPECULATIVE: the precise zinc-binding geometry in the IgG light chain variable region has not been solved crystallographically].
Standard industrial IVIG fractionation (cold-ethanol Cohn fractionation combined with ion-exchange chromatography) routinely employs chelating conditions that deplete trace metals, including zinc, from the final preparation; consequently, the metalloprotease-dependent catalytic fraction of IVIG arrives in vivo in a zinc-depleted, dormant state—providing a biochemical explanation for the failure of IVIG to meet primary endpoints in Phase III clinical trials (Phase II IVIG trial data showing cognitive stabilization without plaque-clearance validation) (Phase II IVIG trial in mild-to-moderate AD)[https://doi.org/10.1016/s1474-4422(13)70014-0].
Oral zinc gluconate at 30 mg/kg in mice produces a transient but reproducible supraphysiological elevation of plasma zinc above t...

SENS category: GlycoSENS